These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17077805)

  • 1. Long-term outcome among men with conservatively treated localised prostate cancer.
    Cuzick J; Fisher G; Kattan MW; Berney D; Oliver T; Foster CS; Møller H; Reuter V; Fearn P; Eastham J; Scardino P;
    Br J Cancer; 2006 Nov; 95(9):1186-94. PubMed ID: 17077805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
    Cuzick J; Berney DM; Fisher G; Mesher D; Møller H; Reid JE; Perry M; Park J; Younus A; Gutin A; Foster CS; Scardino P; Lanchbury JS; Stone S;
    Br J Cancer; 2012 Mar; 106(6):1095-9. PubMed ID: 22361632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
    Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
    Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.
    Cuzick J; Stone S; Fisher G; Yang ZH; North BV; Berney DM; Beltran L; Greenberg D; Møller H; Reid JE; Gutin A; Lanchbury JS; Brawer M; Scardino P
    Br J Cancer; 2015 Jul; 113(3):382-9. PubMed ID: 26103570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
    D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
    J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores.
    Grossklaus DJ; Coffey CS; Shappell SB; Jack GS; Cookson MS
    BJU Int; 2001 Nov; 88(7):722-6. PubMed ID: 11890243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
    Hung AY; Levy L; Kuban DA
    Cancer J; 2002; 8(6):440-4. PubMed ID: 12500852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
    Freedland SJ; Csathy GS; Dorey F; Aronson WJ
    Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer.
    Donovan MJ; Khan FM; Bayer-Zubek V; Powell D; Costa J; Cordon-Cardo C
    BJU Int; 2012 Jan; 109(2):207-13. PubMed ID: 21733075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.
    Berney DM; Fisher G; Kattan MW; Oliver RT; Møller H; Fearn P; Eastham J; Scardino P; Cuzick J; Reuter VE; Foster CS;
    BJU Int; 2007 Dec; 100(6):1240-4. PubMed ID: 17979924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.
    Ahmed HU; Hindley RG; Dickinson L; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
    Lancet Oncol; 2012 Jun; 13(6):622-32. PubMed ID: 22512844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
    D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent.
    Rajab R; Fisher G; Kattan MW; Foster CS; Møller H; Oliver T; Reuter V; Scardino PT; Cuzick J; Berney DM;
    Mod Pathol; 2011 Jan; 24(1):58-63. PubMed ID: 20834240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
    Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.
    Beyer DC; Thomas T; Hilbe J; Swenson V
    Brachytherapy; 2003; 2(2):77-84. PubMed ID: 15062144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.
    D'Amico AV; Wu Y; Chen MH; Nash M; Renshaw AA; Richie JP
    J Urol; 2001 Jan; 165(1):126-9. PubMed ID: 11125380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.